Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Ping An Biomedical Co., Ltd.Bullish
Ping An Biomedical Co., Ltd. has filed a Form F-3 registration statement to offer and sell up to $300 million in securities, including Class A ordinary shares, debt securities, and warrants. As a controlled company with 91.56% of voting power held by a single shareholder, potential future offerings may lead to dilution for public shareholders.…more
Ping An Biomedical Co., Ltd.
Ping An Biomedical will hold an extraordinary general meeting of shareholders on October 29, 2026, to approve a 40-for-1 share consolidation. The company also seeks authorization for further share consolidations ranging from 10-for-1 to 80-for-1 depending on future stock price performance, which will result in adjustments to share counts and authorized capital.…more
Ping An Biomedical Co., Ltd.
Ping An Biomedical will implement a 1-for-40 reverse stock split effective October 23, 2026. Following the split, the number of outstanding shares will be adjusted from 112,867,000 Class A and 12,250,000 Class B shares to approximately 2,821,675 Class A and 306,250 Class B shares. The shares will continue to trade on Nasdaq under the ticker 'PASW' on a split-adjusted basis starting at the market opening on October 23, 2026.…more
5 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
Trading Halt and Resumption Notice
Trading for the specific stock has resumed following a temporary halt. Investors should review the latest company disclosures to inform their trading decisions.…more
●●●●●●●● ●●●●● ●●●●●●
Trading for this security has been temporarily halted pending the release of material news. Investors should exercise caution until further details are disclosed.…more
●●●●●●●● ●●●●● ●●●●●●
Ping An Biomedical has signed a letter of intent to acquire three tumor cell-related medical technology patents for $2 million to $2.5 million. The company views this as a foundational step for its long-term biotech strategy, though it does not expect material near-term revenue.…more
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.